Andrew Dunn, PhD

I’m Andrew Dunn, Co-Founder and CEO of Resurface Therapeutics, a Boston-area biotech working to make lung cancer visible to the immune system again.

For many patients, immunotherapy can’t find the tumor: the cancer switches off the surface signal the immune system uses to recognize danger. At Resurface, we are building a therapy that restores that signal, so the immunotherapies patients already receive can do their job.